Jim Simons Renaissance Technologies
Jim Simons is the founder of Renaissance Technologies, one of the most successful quantitative hedge funds in the world. Before his career in finance, he served as a mathematics professor and made significant contributions to differential geometry. Simons applied his analytical expertise to develop sophisticated, algorithm-driven trading strategies, earning consistently high returns for investors.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
ExxonMobil
XOM
|
+$521M |
| 2 |
Becton Dickinson
BDX
|
+$411M |
| 3 |
GE Aerospace
GE
|
+$361M |
| 4 |
IBM
IBM
|
+$305M |
| 5 |
Philip Morris
PM
|
+$296M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
BCR
CR Bard Inc.
BCR
|
+$455M |
| 2 |
NetEase
NTES
|
+$451M |
| 3 |
Medtronic
MDT
|
+$398M |
| 4 |
NVIDIA
NVDA
|
+$348M |
| 5 |
Netflix
NFLX
|
+$332M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Healthcare | 16.06% |
| 2 | Technology | 13.71% |
| 3 | Financials | 10.21% |
| 4 | Industrials | 9.72% |
| 5 | Consumer Discretionary | 9.38% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
1801
ORIX
IX
$44.1B
| $5.02M | 0.01% |
296,000
-59,000
| -17% | -$999K |
|
1802
Atlanta Braves Holdings Series A
BATRA
$3.63B
| $5.01M | 0.01% |
227,400
+75,400
| +50% | +$1.76M |
|
1803
TriMas Corp
TRS
$1.41B
| $5.01M | 0.01% |
187,300
+67,200
| +56% | +$1.79M |
|
1804
LeMaitre Vascular
LMAT
$1.88B
| $5M | 0.01% |
157,000
-95,600
| -38% | -$3.27M |
|
|
MRNS
1805
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
| $4.99M | 0.01% |
152,919
+76,975
| +101% | +$2.07M |
|
1806
Lexicon Pharmaceuticals
LXRX
$1.05B
| $4.99M | 0.01% |
504,886
+216,800
| +75% | +$2.25M |
|
1807
Natera
NTRA
$45.5B
| $4.98M | 0.01% |
554,400
-4,600
| -0.8% | -$49.7K |
|
1808
Fresenius Medical Care
FMS
$12.6B
| $4.98M | 0.01% |
94,768
+29,768
| +46% | +$1.48M |
|
|
STCN
1809
DELISTED
Steel Connect, Inc. Common Stock
STCN
| $4.97M | 0.01% |
214,080
+17,061
| +9% | +$305K |
|
1810
Bank of N.T. Butterfield & Son
NTB
$2.5B
| $4.97M | 0.01% |
137,000
+5,100
| +4% | +$190K |
|
1811
Alliance Resource Partners
ARLP
$3.23B
| $4.97M | 0.01% |
252,267
+73,077
| +41% | +$1.4M |
|
1812
LiveRamp
RAMP
$2.3B
| $4.95M | 0.01% |
179,745
-391,000
| -69% | -$10.3M |
|
|
CATM
1813
DELISTED
Cardtronics plc Class A Ordinary Shares (UK)
CATM
| $4.95M | 0.01% |
267,200
-336,000
| -56% | -$6.72M |
|
1814
STAAR Surgical
STAA
$1.27B
| $4.93M | 0.01% |
318,400
+48,900
| +18% | +$727K |
|
1815
Fomento Económico Mexicano
FMX
$40B
| $4.93M | 0.01% |
52,500
+50,300
| +2,286% | +$4.59M |
|
|
MRT
1816
DELISTED
MedEquities Realty Trust, Inc.
MRT
| $4.93M | 0.01% |
439,400
+11,700
| +3% | +$133K |
|
|
PBFX
1817
DELISTED
PBF LOGISTICS LP
PBFX
| $4.92M | 0.01% |
234,915
+13,127
| +6% | +$263K |
|
1818
Stratasys
SSYS
$767M
| $4.91M | 0.01% |
246,132
-49,100
| -17% | -$1.07M |
|
|
PVLA
1819
Palvella Therapeutics
PVLA
$2.23B
| $4.91M | 0.01% |
8,126
+3,162
| +64% | +$1.47M |
|
1820
Matsons
MATX
$6.41B
| $4.91M | 0.01% |
164,399
+75,299
| +85% | +$2.13M |
|
1821
Select Water Solutions
WTTR
$2.73B
| $4.9M | 0.01% |
268,800
+221,600
| +469% | +$3.55M |
|
|
RAVN
1822
DELISTED
Raven Industries Inc
RAVN
| $4.9M | 0.01% |
142,700
-16,800
| -11% | -$573K |
|
|
BEDU
1823
DELISTED
Bright Scholar Education Holdings
BEDU
| $4.88M | 0.01% |
65,350
+44,375
| +212% | +$3.87M |
|
1824
UroGen Pharma
URGN
$2.39B
| $4.88M | 0.01% |
131,100
+105,500
| +412% | +$3.76M |
|
|
DRD
1825
DRDGold
DRD
$2.06B
| $4.87M | 0.01% |
1,493,670
-5,600
| -0.4% | -$19.2K |
|
Similar funds
Jim Simons's Q4 2017 Portfolio in Review
As of Q4 2017, Jim Simons held 3,692 positions worth $90.7B, up 6.7% from $85B the previous quarter. Its ten largest holdings account for 8.4% of the portfolio.
Jim Simons's Q4 2017 filing shows 521 new, 1,724 increased, 1,031 reduced and 386 closed positions. Its largest new stake was Alphabet (Google) Class C: 3,773,700 shares worth $197M. The largest sale was CR Bard Inc., an estimated $455M.
By sector, the portfolio is most concentrated in Healthcare at 16% of assets, up from 16% a quarter earlier, followed by Technology and Financials.
- Jim Simons's largest Q4 2017 buy was Alphabet (Google) Class C: 3,773,700 shares worth $197M.
- Jim Simons added most to ExxonMobil in Q4 2017, an estimated $521M increase.
- Jim Simons's biggest Q4 2017 reduction was NetEase, cutting an estimated $451M.
- Jim Simons fully exited CR Bard Inc. in Q4 2017, selling an estimated $455M.
- Jim Simons's ten largest holdings make up 8.4% of its $90.7B portfolio in Q4 2017.
- Jim Simons opened 521 new positions and closed 386 in Q4 2017.
- Jim Simons's portfolio value rose 6.7% quarter-over-quarter to $90.7B.
Based on Renaissance Technologies's 13F filing for Q4 2017, filed 13 Feb 2018.